Bladder cancer has been billed by AstraZeneca as a key growth area for its immunotherapy Imfinzi, an ambition that has now been buoyed by the results of the VOLGA trial. VOLGA was conducted in ...

Please provide your email address to receive an email when new articles are posted on . Cost savings were about $700 per patient per month. Risks for clinically significant drops in Kt/V, potassium or ...

GREECE, N.Y. — Greece police posted on social media showing how drone technology is used to catch suspects. Police say the drone camera was able to give officers real-time information about what was ...

David Pogue is a six-time Emmy winner for his stories on "CBS Sunday Morning," where he's been a correspondent since 2002. Pogue hosts the CBS News podcast "Unsung Science." He's also a New York Times ...

PHOENIX — The Phoenix Police Department announced Thursday it will no longer use non-U.S. license plates on unmarked police vehicles after a video circulated online of one displaying a Mexican license ...

FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit from Keytruda. Agilent Technologies Inc. announced that the U.S. Food and ...

Antioch PD wants to use AI agents for non-emergency calls. Although a human dispatcher would still handle 911 calls, some people in Antioch were not on board with the proposal. Antioch PD wants to add ...

Angela Lipps, seen here in a photo from her GoFundMe page, spent more than five months in jail for a crime she maintains she didn't commit after AI software linked her to a series of bank fraud ...

Get the latest federal technology news delivered to your inbox. FBI searches of U.S. person data collected using a controversial spying authority rose some 35% in 2025, according to an FBI letter to ...

OpenAI's Sam Altman says AI's water concerns are "totally fake." The truth about AI's impact on natural resources is more complicated. Macy is a writer on the AI Team. She covers how AI is changing ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive Keytruda. The U.S. Food and Drug Administration (FDA) has approved PD ...